Elie Needle

Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression

Anastasia G. Henry, Soheil Aghamohammadzadeh, Harry Samaroo et al. · Human Molecular Genetics · 2015 · 249 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

João Paulo Lima Daher, Hisham Abdelmotilib, Xianzhen Hu et al. · Journal of Biological Chemistry · 2015 · 210 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7 <i>H</i> -pyrrolo[2,3- <i>d</i> ]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor

Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward et al. · Journal of Medicinal Chemistry · 2014 · 182 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista, Kalpana Merchant, Ted Barrett et al. · Science Translational Medicine · 2020 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +9

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

Kevin Winthrop, Ann Wouters, Ernest Choy et al. · Arthritis & Rheumatology · 2017 · 123 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17